Hostname: page-component-5c6d5d7d68-vt8vv Total loading time: 0.001 Render date: 2024-08-12T05:34:31.262Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence of Extrapyramidal Side Effects in Patients Receiving Depot Antipsychotic Medication

Published online by Cambridge University Press:  16 April 2020

B. Luft  and
E. Berent
B. Luft
Affiliation:
Community Mental Health, Perth & Kinross, UK
E. Berent
Affiliation:
Community Mental Health, Perth & Kinross, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Long-acting depot antipsychotic medication is associated with extrapyramidal side effects (EPS). This may reduce adherence to medication, and precipitate relapse (1). Clearly, EPS is a major drawback and early detection is essential. However, in an earlier review of patients’ medical notes, we identified only one patient with an examination that recorded the presence of EPS. Despite the fact that a number of rating scales are available. We proposed that the application of these rating scales, would allow us to improve the assessment of EPS.

Method:

All patients prescribed a depot antipsychotic or long-acting risperidone injection, were identified. the Barnes Akathisia Scale (2) was chosen to rate akathisia, a modified Simpson-Angus scale (3) was chosen to rate parkinsonism and the Abnormal Involuntary Movement Scale (4) was chosen to rate tardive dyskinesia.

Results:

A total of 43 patients were evaluated. 23 (53%) patients showed drug induced EPS. the total number of positive cases of akathisia was 12 (28%), and 10 (23%) patients were found to have tardive dyskinesia. 13 (30%) patients were found to have drug induced parkinsonism.

Conclusions:

Our screening programme has identified high rates of previously undiscovered drug induced EPS.

Type
P03-12
Information
European Psychiatry , Volume 24 , Issue S1: 17th EPA Congress - Lisbon, Portugal, January 2009, Abstract book , January 2009 , 24-E1011
Copyright
Copyright © European Psychiatric Association 2009

References

References:

Patel, M.X. David, A.S. Why Aren’t Depots Prescribed More Often, and What Can be Done About It? Advances in Psychiatric Treatment (2005) 11: 203–213Google Scholar
Barnes, T.R.E. (1989) a Rating Scale for Drug-induced Akathisia. British journal of psychiatry, 154, 672-67.Google Scholar
Simpson, G.M. Angus, J.W.S. (1970) A Rating Scale for Extrapyramidal Side Effects. Acta Psychiatrica Scandinavica Supplementum, 212: 11–19CrossRefGoogle Scholar
Weiner, Lang, (1995) Neurology of mental disorders: Advances in Neurology. New York: Raven Press.Google Scholar
Submit a response

Comments

No Comments have been published for this article.